ES2634705T3 - Identificación de antígenos de superficie celular, asociados a tumor para diagnóstico y terapia - Google Patents

Identificación de antígenos de superficie celular, asociados a tumor para diagnóstico y terapia Download PDF

Info

Publication number
ES2634705T3
ES2634705T3 ES10009753.4T ES10009753T ES2634705T3 ES 2634705 T3 ES2634705 T3 ES 2634705T3 ES 10009753 T ES10009753 T ES 10009753T ES 2634705 T3 ES2634705 T3 ES 2634705T3
Authority
ES
Spain
Prior art keywords
associated antigen
tumor associated
tumor
nucleic acid
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10009753.4T
Other languages
English (en)
Spanish (es)
Inventor
Özlem TÜRECI
Ugur Sahin
Gerd Helftenbein
Volker SCHLÜTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ganymed Pharmaceuticals GmbH
Original Assignee
Ganymed Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals GmbH filed Critical Ganymed Pharmaceuticals GmbH
Application granted granted Critical
Publication of ES2634705T3 publication Critical patent/ES2634705T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
ES10009753.4T 2003-09-26 2004-09-23 Identificación de antígenos de superficie celular, asociados a tumor para diagnóstico y terapia Expired - Lifetime ES2634705T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10344799A DE10344799A1 (de) 2003-09-26 2003-09-26 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE10344799 2003-09-26

Publications (1)

Publication Number Publication Date
ES2634705T3 true ES2634705T3 (es) 2017-09-28

Family

ID=34306102

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10009753.4T Expired - Lifetime ES2634705T3 (es) 2003-09-26 2004-09-23 Identificación de antígenos de superficie celular, asociados a tumor para diagnóstico y terapia

Country Status (8)

Country Link
US (6) US7875424B2 (enExample)
EP (22) EP2266617A3 (enExample)
JP (5) JP5144933B2 (enExample)
AU (1) AU2004275500B2 (enExample)
CA (4) CA2539837C (enExample)
DE (1) DE10344799A1 (enExample)
ES (1) ES2634705T3 (enExample)
WO (1) WO2005030250A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
CN1886506B (zh) * 2003-09-29 2012-05-30 中外制药株式会社 在nk细胞中表达的蛋白质
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005013846A1 (de) * 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP1907580A2 (en) * 2005-07-28 2008-04-09 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8404810B2 (en) * 2006-02-17 2013-03-26 Five Prime Therapeutics, Inc. Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
WO2010050190A1 (ja) 2008-10-27 2010-05-06 北海道公立大学法人札幌医科大学 がん幹細胞分子マーカー
US20130017546A1 (en) 2009-10-26 2013-01-17 Externautics S.P.A. Breast Tumor Markers and Methods of Use Thereof
US8921058B2 (en) 2009-10-26 2014-12-30 Externautics Spa Prostate tumor markers and methods of use thereof
WO2011051278A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Lung tumor markers and methods of use thereof
WO2011051276A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Colon and rectal tumor markers and methods of use thereof
US10288617B2 (en) 2009-10-26 2019-05-14 Externautics Spa Ovary tumor markers and methods of use thereof
FR2973380B1 (fr) * 2011-04-01 2018-02-09 C.Ris Pharma Peptides isoles et purifies a partir de testicules de roussette
LT2714071T (lt) 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
TW201302800A (zh) * 2011-06-10 2013-01-16 腫瘤療法 科學股份有限公司 Ｓｅｍａ５ｂ胜肽及含其之疫苗
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
WO2014087626A1 (en) * 2012-12-04 2014-06-12 Oncotherapy Science, Inc. Sema5b peptides and vaccines containing the same
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
EP3194970B1 (en) 2014-09-10 2021-07-28 F. Hoffmann-La Roche AG Immunogenic mutant peptide screening platform
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
GB201520564D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
JP7114477B2 (ja) 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
US20200040103A1 (en) * 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
CA3242459A1 (en) * 2021-12-27 2023-07-06 Memorial Sloan-Kettering Cancer Center Tumor mhc class i expression is associated with interleukin-2 response in melanoma

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
WO1995004068A1 (en) * 1993-07-29 1995-02-09 Isis Pharmaceuticals, Inc. Oligomers for modulating human immunodeficiency virus
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
SE508004C2 (sv) 1996-08-07 1998-08-10 Intermec Ptc Ab Arrangemang för automatisk inställning av printrar samt material därtill
CA2281059A1 (en) * 1997-02-24 1998-08-27 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1998055508A2 (en) * 1997-06-03 1998-12-10 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
US6312922B1 (en) * 1998-02-09 2001-11-06 Genset Complementary DNAs
CA2354369A1 (en) * 1998-12-22 2000-06-29 Genset S.A. Complementary dna's encoding proteins with signal peptides
CA2368098A1 (en) * 1999-06-25 2001-01-04 Genset S.A. Complementary dna's encoding proteins with signal peptides
WO2001054472A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001241541A1 (en) * 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
WO2001077292A2 (en) * 2000-04-07 2001-10-18 Senomyx, Inc. Novel signal transduction molecules
EP1297128A2 (en) * 2000-05-18 2003-04-02 Incyte Genomics, Inc. G-protein coupled receptors
JP2002112793A (ja) * 2000-08-04 2002-04-16 Japan Science & Technology Corp 新規ｇ蛋白質共役受容体
AU2001288237A1 (en) * 2000-08-07 2002-02-18 Curagen Corporation Proteins and nucleic acids encoding g-protein coupled receptors
AU2001293854A1 (en) * 2000-10-04 2002-04-15 Bayer Aktiengesellschaft Regulation of human gpcr-like protein
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
CA2460621A1 (en) * 2001-09-19 2003-03-27 Nuvelo, Inc. Novel nucleic acids and polypeptides
JP2005514051A (ja) * 2001-12-21 2005-05-19 ジーン ロジック インコーポレイテッド 胃癌における遺伝子発現プロファイル
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
US20030170639A1 (en) * 2002-03-11 2003-09-11 Youmin Shu Liver transmembrane protein gene
DE10211088A1 (de) 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7081340B2 (en) * 2002-03-13 2006-07-25 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2003263660A1 (en) * 2003-08-29 2005-03-16 Pantarhei Bioscience B.V. Prenatal diagnosis of down syndrome by detection of fetal rna markers in maternal blood
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie

Also Published As

Publication number Publication date
EP1664113A2 (de) 2006-06-07
WO2005030250A3 (de) 2005-08-18
US9267177B2 (en) 2016-02-23
EP2267013A2 (de) 2010-12-29
CA2814269C (en) 2017-12-19
EP2332979A3 (de) 2011-09-14
EP2332980A3 (de) 2012-02-01
EP2266613A3 (de) 2011-08-03
EP2267014A3 (de) 2012-01-11
EP2266611A2 (de) 2010-12-29
JP5639989B2 (ja) 2014-12-10
EP2266616A2 (de) 2010-12-29
EP2266614A2 (de) 2010-12-29
EP2266611A3 (de) 2011-08-03
CA3096188A1 (en) 2005-04-07
EP2267013A3 (de) 2011-06-08
EP2267012A3 (de) 2011-05-04
EP2266612A3 (de) 2011-11-23
US20160053332A1 (en) 2016-02-25
EP1664113B1 (de) 2018-01-03
JP5804519B2 (ja) 2015-11-04
EP2332983A3 (de) 2012-02-01
EP2266608B1 (de) 2016-05-25
CA2814269A1 (en) 2005-04-07
US9910043B2 (en) 2018-03-06
US9733251B2 (en) 2017-08-15
AU2004275500B2 (en) 2011-07-14
EP2266612A2 (de) 2010-12-29
US20110135640A1 (en) 2011-06-09
JP2016199548A (ja) 2016-12-01
EP2266613B1 (de) 2016-12-14
EP2266614A3 (de) 2012-01-11
CA3096188C (en) 2022-06-07
EP2266615A2 (de) 2010-12-29
EP2267012B1 (de) 2017-04-26
EP2295077A3 (de) 2011-08-10
EP2272534A2 (de) 2011-01-12
EP2332983A2 (de) 2011-06-15
US20130280166A1 (en) 2013-10-24
EP2295077A2 (de) 2011-03-16
US20160195539A1 (en) 2016-07-07
EP2272534A3 (de) 2011-06-15
CA2984653A1 (en) 2005-04-07
CA2539837A1 (en) 2005-04-07
EP2266612B1 (de) 2018-01-03
EP2332981A2 (de) 2011-06-15
EP2266609A2 (de) 2010-12-29
EP2332981A3 (de) 2012-02-01
US20080166340A1 (en) 2008-07-10
EP2266617A2 (de) 2010-12-29
EP2266618A2 (de) 2010-12-29
CA2984653C (en) 2020-12-15
JP5144933B2 (ja) 2013-02-13
EP2266608A2 (de) 2010-12-29
EP2267012A2 (de) 2010-12-29
JP2014221760A (ja) 2014-11-27
EP2267013B1 (de) 2015-11-11
EP2266610A3 (de) 2012-01-25
EP2332979A2 (de) 2011-06-15
EP2266616A3 (de) 2011-09-14
JP5969538B2 (ja) 2016-08-17
JP2013063975A (ja) 2013-04-11
DE10344799A1 (de) 2005-04-14
US9139880B2 (en) 2015-09-22
US20150376718A1 (en) 2015-12-31
EP2266615A3 (de) 2011-09-21
WO2005030250A2 (de) 2005-04-07
EP2267014A2 (de) 2010-12-29
EP2266610A2 (de) 2010-12-29
US7875424B2 (en) 2011-01-25
AU2004275500A1 (en) 2005-04-07
EP2266617A3 (de) 2012-01-25
EP2266609A3 (de) 2012-02-01
EP2266618A3 (de) 2011-06-22
EP2332980A2 (de) 2011-06-15
EP2267011A2 (de) 2010-12-29
JP6196350B2 (ja) 2017-09-13
JP2007506417A (ja) 2007-03-22
CA2539837C (en) 2017-12-19
EP2266613A2 (de) 2010-12-29
JP2012110324A (ja) 2012-06-14
EP2266608A3 (de) 2012-01-25
EP2267011A3 (de) 2011-05-18

Similar Documents

Publication Publication Date Title
RU2360923C2 (ru) Новый лиганд рецептора цитокина zcytor17
ES2625316T3 (es) Neuquinasa, una proteína corriente abajo de neuregulina
ES2364147T3 (es) Polipéptidos de fusión capaces de activar receptores.
JP2010029207A (ja) ＨＭＧ蛋白質（ｈｉｇｈｍｏｂｉｌｉｔｙｇｒｏｕｐｐｒｏｔｅｉｎ）遺伝子の核酸配列およびそれらの使用
CN102775490A (zh) 具有趋化活性的分泌蛋白及其应用
JP2001518287A (ja) アポトーシス関連化合物およびその使用
ES2424976T3 (es) Isoformas relativas al cáncer de componentes de complejos de factores de transcripción como biomarcadores y dianas de fármacos
EP3583117B1 (en) In vitro method for fusing two or more cells, in vitro, method for delivering a gene of interest, and pharmaceutical composition for use in the treatment of a disease
US11028139B2 (en) Recombinant protein for preventing or treating tissue fibrosis and composition for preventing or treating tissue fibrosis comprising the same
RU2535971C2 (ru) Тимус-специфический белок
WO2017117331A1 (en) Methods for identifying and treating hemoglobinopathies
US20030220249A1 (en) Factors for angiogenesis, vasculogenesis, cartilage formation, bone formation, and methods of use thereof
KR20070073802A (ko) Ｗｎｔ 단백질 및 암의 검출 및 치료
ES2401233T3 (es) Isoformas del receptor tipo 5 de somatostatina humana producidas por tratamiento alternativo y pares de oligonucleótidos para la detección de las mismas por PCR
KR20050092366A (ko) 펩티드, 이에 대한 항체, 및 중추 신경계 손상의 치료에있어서의 이의 용도
WO2006008542A1 (en) Cell cycle phase markers
CN103626865A (zh) 具有趋化活性的分泌蛋白及其编码序列和医药用途
CN108452307A (zh) 人miRNA-493-3p的抑制剂在制备治疗肾纤维化药物中的应用
JPWO1997032982A1 (ja) ヒト接着分子オクルディン
Khavinson et al. Peptide regulation of aging: 35-year research experience
JP7764502B2 (ja) 環状ＲＮＡ Ｃｉｒｃ－ＡＣＥ２翻訳によるポリペプチド及びその使用
CN115896115B (zh) 靶向npm蛋白的肽适配子及其多肽药物和应用
JP5648927B2 (ja) Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
Chinen et al. Isolation and mapping of the human beta-signal sequence receptor gene (SSR2)
US20050054094A1 (en) SPRR1A and axonal regeneration